Accuray (NASDAQ:ARAY – Get Rating) will issue its quarterly earnings data after the market closes on Wednesday, February 1st. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Accuray has set its FY 2023 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.
Accuray (NASDAQ:ARAY – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.05). The company had revenue of $96.49 million during the quarter, compared to analysts’ expectations of $105.11 million. Accuray had a negative net margin of 2.33% and a negative return on equity of 19.27%. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Accuray Price Performance
ARAY stock opened at $2.48 on Wednesday. The company has a debt-to-equity ratio of 3.63, a current ratio of 1.74 and a quick ratio of 0.95. The business has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $2.18. The firm has a market capitalization of $232.57 million, a PE ratio of -22.55 and a beta of 1.57. Accuray has a 1 year low of $1.70 and a 1 year high of $4.36.
Insider Activity at Accuray
Hedge Funds Weigh In On Accuray
Institutional investors have recently bought and sold shares of the company. MetLife Investment Management LLC grew its position in Accuray by 131.9% in the 1st quarter. MetLife Investment Management LLC now owns 42,624 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 24,246 shares in the last quarter. Teton Advisors Inc. grew its position in Accuray by 14.3% in the 1st quarter. Teton Advisors Inc. now owns 40,000 shares of the medical equipment provider’s stock valued at $132,000 after acquiring an additional 5,000 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Accuray in the 1st quarter valued at about $104,000. Jane Street Group LLC grew its position in shares of Accuray by 290.5% during the second quarter. Jane Street Group LLC now owns 48,441 shares of the medical equipment provider’s stock worth $95,000 after buying an additional 36,036 shares in the last quarter. Finally, Quantbot Technologies LP grew its position in shares of Accuray by 540.2% during the second quarter. Quantbot Technologies LP now owns 46,181 shares of the medical equipment provider’s stock worth $90,000 after buying an additional 38,968 shares in the last quarter. 63.42% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Accuray in a research report on Wednesday, October 12th. They issued a “hold” rating for the company.
Accuray Company Profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
- Get a free copy of the StockNews.com research report on Accuray (ARAY)
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.